|
1
|
Abuzaid H, Abdelrazig S, Ferreira L, Collins HM, Kim DH, Lim KH, Kam TS, Turyanska L, Bradshaw TD. Apoferritin-Encapsulated Jerantinine A for Transferrin Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy. ACS OMEGA 2022; 7:21473-21482. [PMID: 35785302 PMCID: PMC9244903 DOI: 10.1021/acsomega.2c00997] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Accepted: 05/19/2022] [Indexed: 05/03/2023]
Abstract
The O-acetyl (or acetate) derivative of the Aspidosperma alkaloid Jerantinine A (JAa) elicits anti-tumor activity against cancer cell lines including mammary carcinoma cell lines irrespective of receptor status (0.14 < GI50 < 0.38 μM), targeting microtubule dynamics. By exploiting breast cancer cells' upregulated transferrin receptor 1 (TfR1) expression and apoferritin (AFt) recognition, we sought to develop an AFt JAa-delivery vehicle to enhance tumor-targeting and reduce systemic toxicity. Optimizing pH-mediated reassembly, ∼120 JAa molecules were entrapped within AFt. Western blot and flow cytometry demonstrate TfR1 expression in cancer cells. Enhanced internalization of 5-carboxyfluorescein-conjugated human AFt in SKBR3 and MDA-MB-231 cancer cells is observed compared to MRC5 fibroblasts. Accordingly, AFt-JAa delivers significantly greater intracellular JAa levels to SKBR3 and MDA-MB-231 cells than naked JAa (0.2 μM) treatment alone. Compared to naked JAa (0.2 μM), AFt-JAa achieves enhanced growth inhibition (2.5-14-fold; <0.02 μM < GI50 < 0.15 μM) in breast cancer cells; AFt-JAa treatment results in significantly reduced clonal survival, more profound cell cycle perturbation including G2/M arrest, greater reduction in cell numbers, and increased apoptosis compared to the naked agent (p < 0.01). Decreased PLK1 and Mcl-1 expression, together with the appearance of cleaved poly (ADP-ribose)-polymerase, corroborate the augmented potency of AFt-JAa. Hence, we demonstrate that AFt represents a biocompatible vehicle for targeted delivery of JAa, offering potential to minimize toxicity and enhance JAa activity in TfR1-expressing tumors.
Collapse
Affiliation(s)
- Haneen Abuzaid
- School
of Pharmacy, Biodiscovery Institute, The
University of Nottingham, University Park, Nottingham NG7 2RD, U.K.
| | - Salah Abdelrazig
- School
of Pharmacy, Biodiscovery Institute, The
University of Nottingham, University Park, Nottingham NG7 2RD, U.K.
| | - Lenny Ferreira
- School
of Pharmacy, Biodiscovery Institute, The
University of Nottingham, University Park, Nottingham NG7 2RD, U.K.
| | - Hilary M. Collins
- School
of Pharmacy, Biodiscovery Institute, The
University of Nottingham, University Park, Nottingham NG7 2RD, U.K.
| | - Dong-Hyun Kim
- School
of Pharmacy, Biodiscovery Institute, The
University of Nottingham, University Park, Nottingham NG7 2RD, U.K.
| | - Kuan-Hon Lim
- The
University of Nottingham Malaysia, Block B, Malaysia Campus, Jalan Broga, 43500 Semenyih, Selangor, Malaysia
| | - Toh-Seok Kam
- Department
of Chemistry, Faculty of Science, The University
of Malaya, 50603 Kuala Lumpur, Malaysia
| | - Lyudmila Turyanska
- Faculty
of Engineering, The University of Nottingham, Additive Manufacturing Building,
Jubilee Campus, University Park, Nottingham NG7 2RD, U.K.
| | - Tracey D. Bradshaw
- School
of Pharmacy, Biodiscovery Institute, The
University of Nottingham, University Park, Nottingham NG7 2RD, U.K.
| |
Collapse
|